Eli Lilly’s obesity pill, orforglipron, branded as Foundayo, received FDA approval, positioning it against Novo Nordisk’s Wegovy oral pill. While both drugmakers have focused on offering alternatives to injections, Lilly’s pill is seen as appealing due to its absence of strict intake restrictions and wider distribution potential. However, Wegovy has gained quick popularity following its launch, and price competition is heating up, with Lilly dropping the cash price of Foundayo to match Wegovy at $299 per month. Efficacy studies show Wegovy leading in weight loss results, though both medications display similar side effects. Additionally, concerns about political influences in the FDA approval process have surfaced.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/
